Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperdal CONSTA Augmentation in Frequently-relapsing Bipolar Disorder
NCT00094926Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Risperdal Consta + TAU with Placebo + TAU (2 arms). Primary endpoint: Time to Relapse at 52 weeks. Started May 2004; status: completed.
02
Drugs
risperidone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00094926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094926.